FDA Recalls Helix CBD Clinical Cream for Manufacturing Process Violations
Parker Laboratories is recalling Helix CBD Clinical Cream due to manufacturing process deviations. The FDA Class II recall affects batches distributed nationwide and internationally; consumers should discontinue use and contact the manufacturer.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall due to manufacturing process deviations with no reported illnesses or injuries. The voluntary, precautionary recall fits the rubric criteria for moderate severity.
Plain-English summary
Parker Laboratories has recalled Helix CBD Clinical Cream (Menthol 7.4%) in multiple package sizes due to Good Manufacturing Practice (CGMP) deviations. The affected products include 3 gm pouches, 2 fl. oz. tubes, and 4 fl. oz. tubes with specific lot numbers: J1121011 (expiring 12/21/2023), A0921009 (expiring 8/18/2023), and A0921008 (expiring 8/18/2023).
The recall was initiated on August 2, 2023, after the FDA classified the issue as a Class II safety concern. Manufacturing deviations were identified during the agency's review of the product's production process. No illnesses or injuries have been reported in connection with this product.
The affected cream was distributed nationwide in the United States, as well as internationally to Singapore, Korea, and Hong Kong. Consumers who have purchased these products should stop using them and contact Parker Laboratories for return or disposal instructions.
This recall was initiated voluntarily by the manufacturer and terminated on June 3, 2024, once corrective manufacturing measures were completed.
The recalled product
- Product
- Helix CBD Clinical Cream (Menthol 7.4%), packaged in a)3 gm pouches (NDC30775-054-01), b)2 fl. oz. tubes (NDC 30775-054-02), and c) 4 fl. oz. tubes (NDC 30775-054-04), Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004
- Manufacturer
- Parker Laboratories, Inc.
- Category
- Drug — Topical Cream
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: a) J1121011
- Exp. Date 12/21/2023
- b) A0921009
- Exp. Date 8/18/2023
- c) A0921008
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27